Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other Non-Current Assets (2016 - 2025)

Guided Therapeutics' Other Non-Current Assets history spans 12 years, with the latest figure at $17000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $17000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $17000.0, a 0.0% change, with the full-year FY2025 number at $17000.0, changed 0.0% from a year prior.
  • Other Non-Current Assets hit $17000.0 in Q4 2025 for Guided Therapeutics, roughly flat from $17000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for GTHP hit a ceiling of $18000.0 in Q1 2021 and a floor of $17000.0 in Q2 2021.
  • Historically, Other Non-Current Assets has averaged $17050.0 across 5 years, with a median of $17000.0 in 2021.
  • The widest YoY moves for Other Non-Current Assets: up 5.88% in 2021, down 96.55% in 2021.
  • Tracing GTHP's Other Non-Current Assets over 5 years: stood at $17000.0 in 2021, then changed by 0.0% to $17000.0 in 2022, then changed by 0.0% to $17000.0 in 2023, then changed by 0.0% to $17000.0 in 2024, then changed by 0.0% to $17000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for GTHP at $17000.0 in Q4 2025, $17000.0 in Q3 2025, and $17000.0 in Q2 2025.